shutterstock_1464867716_oleksandrshnuryk
OleksandrShnuryk / Shutterstock.com
7 December 2021AmericasMuireann Bolger

Fresenius in patent dispute over hypocalcemia treatment

Fresenius Kabi is facing a lawsuit by two Pharmasphere subsidiaries over claims that it infringed a patent covering a treatment for hypocalcemia, a condition where the blood sugar (glucose) level is lower than normal.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
15 April 2019   Fresenius Kabi has submitted a petition for inter partes review of US patent number 9,856,287, a patent owned by Amgen.
Americas
6 January 2017   Healthcare company Fresenius Kabi has targeted Sagent Pharmaceuticals in a patent infringement lawsuit centring on generic versions of Naropin.

More on this story

Americas
15 April 2019   Fresenius Kabi has submitted a petition for inter partes review of US patent number 9,856,287, a patent owned by Amgen.
Americas
6 January 2017   Healthcare company Fresenius Kabi has targeted Sagent Pharmaceuticals in a patent infringement lawsuit centring on generic versions of Naropin.

More on this story

Americas
15 April 2019   Fresenius Kabi has submitted a petition for inter partes review of US patent number 9,856,287, a patent owned by Amgen.
Americas
6 January 2017   Healthcare company Fresenius Kabi has targeted Sagent Pharmaceuticals in a patent infringement lawsuit centring on generic versions of Naropin.